Pharma News

Novartis has entered into an agreement to acquire Chinook Therapeutics, a Seattle, WA, based clinical stage biopharmaceutical company with two high-value, late-stage medicines in development for rare, severe chronic kidney diseases.

Roche announced that the cobas HPV test for use on the cobas 6800/8800 Systems has been awarded World Health Organization (WHO) prequalification. WHO prequalification expands the availability of this critical HPV screening tool in countries that rely on the global organisation’s list in making purchasing and implementation decisions.

Cancer is caused by changes in DNA sequences (genes) and subsequently, the function of their end product, proteins. In a recent study, a team of researchers proposed to use the architecture of a specific DNA to control the synthesis of the protein factor, as to regulate the progression of some cancers, especially lung, breast, and glioblastoma (brain tumour).

Therapeutic nanocarriers engineered from adult skin cells can curb inflammation and tissue injury in damaged mouse lungs, new research shows, hinting at the promise of a treatment for lungs severely injured by infection or trauma.

Researchers conducted experiments in cell cultures and mice to demonstrate the therapeutic potential of these nanoparticles, which are extracellular vesicles similar to the ones circulating in humans’ bloodstream and biological fluids that carry messages between cells.

Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is a fatal motor neuron disease that causes people to gradually lose control of their muscles. There is no cure, and current treatments focus on reducing symptoms and providing supportive care. Reporting June 1 in the journal Cell Stem Cell, researchers from Japan show in an early clinical trial that the Parkinson's disease drug ropinirole is safe to use in ALS patients and delayed disease progression by 27.9 weeks on average.

Government has banned 14 FDCs after recommendations of the Expert Committee which stated that there is no therapeutic justification for these FDCs and the FDCs may involve risk to human beings.

The Central Government in exercise of the powers conferred by section 26A of the Drugs and Cosmetics act 1940 (23 of 1940) prohibited the manufacture for sale, sale and distribution for human use of 14 drug FDCs (fixed dose combinations).

An international team, led by UBC Okanagan researchers, suggests a simple tweak to the first meal of the day might help people living with Type 2 diabetes (T2D) better control their blood sugar levels.

The early stages of embryonic development contain many of life’s mysteries. Unlocking these mysteries can help us better understand early development and birth defects, and help develop new regenerative medicine treatments.

Researchers based at the Australian Regenerative Medicine Institute (ARMI) at Monash University have characterised a critical time in mammalian embryonic development using powerful and innovative imaging techniques, with their work published in Nature Communications.

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.

Lexicon Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved INPEFA (sotagliflozin), a once-daily oral tablet to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with :
heart failure or
type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors.